Literature DB >> 18196239

Highlights of the annual congress of the European Association of Nuclear Medicine, Copenhagen 2007.

Juhani Knuuti1, Roland Hustinx.   

Abstract

INTRODUCTION: The Annual Congress of the European Association of Nuclear Medicine took place in Copenhagen on October 13-17, 2007. The event is the major scientific and professional effort in the field of nuclear medicine in Europe. The most important developments in the fields of instrumentation, radionuclide production, radiochemistry, radiotherapy, as well as the clinical imaging fields of neurology, cardiology, oncology, and general sciences were reported.
OBJECTIVE: This paper emphasizes the major findings and trends at this important gathering. This review is, however, only a brief summary of the large amount of data discussed.

Entities:  

Mesh:

Year:  2008        PMID: 18196239     DOI: 10.1007/s00259-007-0674-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  12 in total

1.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

2.  18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer.

Authors:  Giuseppe Lucio Cascini; Antonio Avallone; Paolo Delrio; Cesare Guida; Fabiana Tatangelo; Pietro Marone; Luigi Aloj; Francesco De Martinis; Pasquale Comella; Valerio Parisi; Secondo Lastoria
Journal:  J Nucl Med       Date:  2006-08       Impact factor: 10.057

3.  In vitro and in vivo evaluation of [123I]-VEGF165 as a potential tumor marker.

Authors:  Bart Cornelissen; Ruth Oltenfreiter; Veerle Kersemans; Ludovicus Staelens; Francis Frankenne; Jean-Michel Foidart; Guido Slegers
Journal:  Nucl Med Biol       Date:  2005-07       Impact factor: 2.408

4.  How do HYNIC-conjugated peptides bind technetium? Insights from LC-MS and stability studies.

Authors:  Robert C King; M Bashir-Uddin Surfraz; Stefano C G Biagini; Philip J Blower; Stephen J Mather
Journal:  Dalton Trans       Date:  2007-09-25       Impact factor: 4.390

5.  Colorectal liver metastases: CT, MR imaging, and PET for diagnosis--meta-analysis.

Authors:  Shandra Bipat; Maarten S van Leeuwen; Emile F I Comans; Milan E J Pijl; Patrick M M Bossuyt; Aeilko H Zwinderman; Jaap Stoker
Journal:  Radiology       Date:  2005-08-11       Impact factor: 11.105

6.  Technetium-binding in labelled HYNIC-peptide conjugates: role of coordinating amino acids.

Authors:  M Bashir-Uddin Surfraz; Robert King; Stephen J Mather; Stefano Biagini; Philip J Blower
Journal:  J Inorg Biochem       Date:  2009-05-03       Impact factor: 4.155

7.  Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis.

Authors:  Karen Kinkel; Ying Lu; Marcus Both; Robert S Warren; Ruedi F Thoeni
Journal:  Radiology       Date:  2002-09       Impact factor: 11.105

8.  Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial.

Authors:  Fabienne Iten; Beat Müller; Christian Schindler; Christoph Rochlitz; Daniel Oertli; Helmut R Mäcke; Jan Müller-Brand; Martin A Walter
Journal:  Clin Cancer Res       Date:  2007-11-15       Impact factor: 12.531

9.  Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?

Authors:  P Antunes; M Ginj; H Zhang; B Waser; R P Baum; J C Reubi; H Maecke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-16       Impact factor: 10.057

10.  Disseminated iodine-avid lung metastases in differentiated thyroid cancer: a challenge to 124I PET.

Authors:  Lutz S Freudenberg; Walter Jentzen; Stefan P Müller; Andreas Bockisch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-11-20       Impact factor: 10.057

View more
  1 in total

1.  Binding of [123I]iodobenzamide to the rat D2 receptor after challenge with various doses of methylphenidate: an in vivo imaging study with dedicated small animal SPECT.

Authors:  Susanne Nikolaus; Christina Antke; Markus Beu; Konstantin Kley; Andreas Wirrwar; Joseph P Huston; Hans-Wilhelm Müller
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-26       Impact factor: 9.236

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.